journal
MENU ▼
Read by QxMD icon Read
search

ESMO Open

journal
https://read.qxmd.com/read/30622744/immunotherapy-for-hepatocellular-carcinoma-current-status-and-future-perspectives
#1
REVIEW
Takuji Okusaka, Masafumi Ikeda
The discovery of the immune checkpoint mechanism has contributed greatly to recent advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody ipilimumab was first approved as a therapeutic drug for malignant melanoma in the USA in 2011; since then, antiprogrammed cell death 1 (PD-1) antibody and antiprogrammed death-ligand 1 (PD-L1) antibody have also been approved and clinically introduced and are indicated for the treatment of various cancers. Numerous clinical studies are now underway to evaluate the efficacy of immune checkpoint inhibitors for patients with many kinds of cancer, including hepatocellular carcinoma (HCC), and the outcomes of these trials are highly anticipated...
2018: ESMO Open
https://read.qxmd.com/read/30622743/cancer-research-in-the-era-of-immunogenomics
#2
REVIEW
Yochai Wolf, Yardena Samuels
The most meaningful advancement in cancer treatment in recent years has been the emergence of immunotherapy. Checkpoint inhibitor blockade and adoptive T cell therapy have shown remarkable clinical effects in a wide range of tumour types. Despite these advances, many tumours do not respond to these treatments, which raises the need to further investigate how patients can benefit from immunotherapy. This effort can now take advantage of the recent technological progress in single-cell, high-throughput sequencing and computational efforts...
2018: ESMO Open
https://read.qxmd.com/read/30592465/correction-po-194-novel-potential-targets-for-hakai-oncogene-during-tumour-progression
#3
(no author information available yet)
[This corrects the article DOI: 10.1136/esmoopen-2018-EACR25.230.].
2018: ESMO Open
https://read.qxmd.com/read/30559981/management-of-young-women-with-early-breast-cancer
#4
Francesca Poggio, Matteo Lambertini, Claudia Bighin, Benedetta Conte, Eva Blondeaux, Alessia D'Alonzo, Chiara Dellepiane, Francesco Boccardo, Lucia Del Mastro
Breast cancer is still the most frequent cancer diagnosed in women aged ≤40 years and the primary cause of death in this age group. The management of these patients needs a dedicated approach involving a multidisciplinary team that takes into account their treatment and survivorship issues. The present review aims to provide a perspective on the many challenges associated with treatment of young women with early breast cancer. We will focus on the standard (neo)adjuvant treatment, highlighting the paucity of age-specific results about the available genomic signatures, the groundbreaking landscape of adjuvant endocrine therapy and the relevant issue of the fertility preservation...
2018: ESMO Open
https://read.qxmd.com/read/30559980/in-the-literature-december-2018
#5
Valentina Gambardella, Tania Fleitas, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30559979/evaluation-of-time-to-failure-of-strategy-as-an-alternative-surrogate-endpoint-in-patients-with-lung-cancer-with-egfr-mutations
#6
Yuki Shinno, Yasushi Goto, Sho Watanabe, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Background: Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring EGFR mutations. Among these patients, progression-free survival (PFS) has been used as a surrogate endpoint; however, it may not correlate with overall survival (OS) due to crossover. Time to failure of strategy (TFS) has been proposed as an alternative endpoint in advanced colorectal cancer clinical trials where multiple effective therapies are provided either in combination or sequentially...
2018: ESMO Open
https://read.qxmd.com/read/30555723/chemotherapy-versus-erlotinib-as-second-line-treatment-in-patients-with-advanced-non-small-cell-lung-cancer-and-wild-type-epidermal-growth-factor-receptor-an-individual-patient-data-ipd-analysis
#7
REVIEW
Marina Chiara Garassino, Tomoya Kawaguchi, Vanesa Gregorc, Eliana Rulli, Masahiko Ando, Silvia Marsoni, Shun-Ichi Isa, Silvia Novello, Gabriella Farina, Sandro Barni, Valter Torri, Michela Cinquini
The efficacy of second-line treatment in patients with epidermal growth factor receptor (EGFR) wild-type tumours is still debatable. We assessed the efficacy of a standard second-line chemotherapy compared with erlotinib in an individual patient data approach for meta-analysis. The primary endpoint was overall survival (OS), and secondary endpoint was progression-free survival (PFS). Both were compared by log-rank test. The 'restricted mean survival time' (RMST) was estimated in each study and the difference in mean survival time up to the last available time point was calculated...
2018: ESMO Open
https://read.qxmd.com/read/30498582/all-change-closing-the-gender-gap-in-oncology
#8
EDITORIAL
Josep Tabernero
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30498581/dose-escalation-of-axitinib-on-disease-progression-as-a-strategy-in-the-treatment-of-metastatic-renal-cell-carcinoma
#9
Gary Joseph Doherty, Deirdre Lynskey, Athena Matakidou, Kate Fife, Tim Eisen
Introduction: The AXIS trial established axitinib as a standard of care treatment for patients with metastatic renal cell carcinoma (mRCC) after failure of a prior tyrosine kinase inhibitor. Axitinib dosing begins at 5  mg twice daily, with escalation of doses to 7  and 10  mg after consecutive 2-week intervals if tolerated (as per the drug label). Given clinical concerns about drug-related toxicity, we have used a pragmatic strategy where dose escalations were made only after disease progression or where rapid responses were clinically required...
2018: ESMO Open
https://read.qxmd.com/read/30430024/biosimilars-in-oncology
#10
Josep Tabernero
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30430023/report-from-the-esmo-2018-presidential-symposium-radiotherapy-to-the-primary-tumour-for-men-with-newly-diagnosed-metastatic-prostate-cancer-survival-results-from-stampede
#11
https://read.qxmd.com/read/30426973/prognostic-nutritional-index-as-an-independent-prognostic-factor-in-locoregionally-advanced-squamous-cell-head-and-neck-cancer
#12
Gema Bruixola, Javier Caballero, Federica Papaccio, Angelica Petrillo, Aina Iranzo, Miguel Civera, Miriam Moriana, Neus Bosch, Maria Maroñas, Ines González, Miguel Pastor, Andrés Cervantes
Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions...
2018: ESMO Open
https://read.qxmd.com/read/30426972/prognostic-nutritional-index-an-easy-nutritional-screening-for-patients-with-head-and-neck-cancer
#13
Paolo Bossi
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30425850/introducing-the-metastatic-breast-cancer-project-a-novel-patient-partnered-initiative-to-accelerate-understanding-of-mbc
#14
https://read.qxmd.com/read/30425849/efficacy-and-safety-of-ramucirumab-containing-chemotherapy-in-patients-with-pretreated-metastatic-gastric-neuroendocrine-carcinoma
#15
Saori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Elizabeth M Nonte, Sudhakar Chintharlapalli, Aejaz Nasir, Takeshi Kuwata, Kohei Shitara
Background: Ramucirumab (RAM), a monoclonal antibody for vascular endothelial growth factor 2 (VEGFR2), has been effective for advanced gastric adenocarcinoma (AC). However, little is known about the efficacy of RAM-containing chemotherapy (RAM-CTx) in gastric neuroendocrine carcinoma (G-NEC). Methods: We retrospectively analysed and compared the clinical outcomes of patients (pts) with G-NEC receiving RAM-CTx, G-NEC receiving CTx without RAM and AC receiving RAM-CTx in our hospital...
2018: ESMO Open
https://read.qxmd.com/read/30425848/correction-preparing-for-the-incoming-wave-of-biosimilars-in-oncology
#16
(no author information available yet)
[This corrects the article DOI: 10.1136/esmoopen-2018-000420.].
2018: ESMO Open
https://read.qxmd.com/read/30425847/esmo-2018-presidential-symposium-impassion130-atezolizumab-nab-paclitaxel-in-triple-negative-breast-cancer
#17
Peter Schmid
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30425846/in-the-literature-october-2018
#18
Desamparados Roda, Valentina Gambardella, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://read.qxmd.com/read/30425845/precision-oncology-separating-the-wheat-from-the-chaff
#19
Jordi Remon, Rodrigo Dienstmann
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.
2018: ESMO Open
https://read.qxmd.com/read/30425844/risk-factors-for-the-development-of-brain-metastases-in-patients-with-her2-positive-breast-cancer
#20
Christian Maurer, Lorraine Tulpin, Michel Moreau, Cristina Dumitrescu, Evandro de Azambuja, Marianne Paesmans, Jean-Marie Nogaret, Martine J Piccart, Ahmad Awada
Background: Patients with metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM in patients with HER2+ BC and to report on their outcome. Methods: This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium. Statistical analyses were conducted with SAS V...
2018: ESMO Open
journal
journal
53848
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"